614 McKinley Place N.E.
234 articles with Bio-Techne
Bio-Techne To Host Conference Call On February 2, 2021 To Announce Second Quarter 2021 Financial Results
Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday, February 2, 2021 , at 8:00 a.m. CST to review second quarter 2021 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CST Date: February 2, 2
ScaleReady’s mission is to make the business of cell and gene therapy practical and viable by providing the most simple, scalable and versatile manufacturing platform in the industry
Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the 39 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 2:00 p.m. EST . A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investo
Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics (NASDAQ: RGLS) announced a collaboration to support Regulus with biomarker analysis for the clinical development of RGLS4326, an Autosomal Dominant Polycystic Kidney Disease (ADPKD) treatment. Regulus has utilized two Bio-Techne branded product lines, ProteinSimple and
- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the Stephens Annual Investment Conference 2020 on Tuesday, November 17, 2020 at 3:00 p.m. EST . A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Rela
Bio-Techne Corporation reported its financial results for the first quarter ended September 30, 2020.
Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended September 30, 2020.
Bio-Techne Corporation announced that Jim Hippel, Chief Financial Officer, will present at the 29th Annual Credit Suisse Virtual Healthcare Conference on Wednesday, November 11, 2020 at 4:15 p.m. EST.
CE Mark Approval Granted to Kantaro COVID-SeroKlir and COVID-SeroIndex Quantitative Antibody Test Kits
-The quantitative test kits detect the level of COVID-19 antibodies that correlate to virus neutralization -Kantaro test achieves 97.8% sensitivity and 99.6% specificity for the presence of COVID-19 antibodies -Because no proprietary equipment is required, the Kantaro kits are scalable across global testing laboratories
Bio-Techne Announces Commercial Release Of New SARS-CoV-2 Multi-Antigen Serology Assay Kit For Simple Western
New serology assay accelerates COVID-19 research and vaccine development through rapid characterization of human immune response to multiple SARS-CoV-2 antigens
Bio-Techne Corporation, a leading provider of proteins, antibodies and cytokines announced that its Woburn, Massachusetts site received ISO 13485:2016 certification for Medical Device and Quality Management Systems.
Bio-Techne To Host Conference Call On November 5, 2020 To Announce First Quarter 2021 Financial Results
Bio-Techne Corporation announced that management will host a conference call and webcast on Thursday, November 5, 2020, at 8:00 a.m. CST to review first quarter 2021 financial results.
Bio-Techne Corporation announced the opening of its new Canadian office located in Toronto.
Bio-Techne Corporation announced the grand opening of its approximately 61,000 square foot state-of-the-art GMP manufacturing facility.
Bio-Techne Announces Publication Of ExoDx Prostate Test Study In Patients With Prior Negative Prostate Biopsy
Bio-Techne Corporation announced an important publication in BMC Urology, entitled A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy.
Bio-Techne Announces Commercial Release Of New Co-Detection Assays For Simultaneous Detection Of RNA And Protein On The Same Sample
Bio-Techne Corporation (NASDAQ:TECH) today announced the expansion of the Advanced Cell Diagnostics (ACD)-branded RNAscope™ technology with release of the new RNA-Protein Co-Detection Assays. The RNAs
Bio-Techne Corporation announced that the B-MoGen Biotechnologies portfolio of genome engineering services, GMP therapeutic manufacturing services, and its proprietary transposon-transposase gene transfer system, TcBuster™, will be rebranded as R&D Systems.
Bio-Techne Corporation and QIAGEN N.V. announced the expansion and extension of a non-exclusive partnership to co-market exosome technology to existing and potential biopharma partners as well as the joint development of new exosome based products.
Bio-Techne And Hall Of Famer Cal Ripken Jr -Announce Partnership To Raise Awareness And Education To Empower Men With Prostate Cancer
Bio-Techne Corporation announced that Exosome Diagnostics, a Bio-Techne brand, has established a new partnership with Hall of Famer and baseball's all-time "Iron Man", Cal Ripken Jr. This year marks 25 years since Ripken played in his 2,131st consecutive game, eclipsing the thought to be unbreakable record of 2,130 set by the legendary Lou Gehrig.
Bio-Techne Corporation announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 2020 Wells Fargo Virtual Healthcare Conference on Wednesday, September 9, 2020 at 11:20 a.m. EDT.